Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum sAPO-1/Fas levels in multiple sclerosis

S Bansil1, C R Holtz, S D Cook

  • 1Department of Neurosciences, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark 07103, USA.

Acta Neurologica Scandinavica
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful conservative management of urinary tract rupture in dogs and cats: 52 cases (2003-2024).

The Journal of small animal practice·2025
Same author

Multimodality diagnostic imaging findings in a dog with a traumatic pulmonary pseudocyst.

The Journal of small animal practice·2020
Same author

Joint Laxity and Proprioception in the Knee.

The Physician and sportsmedicine·2016
Same author

The effect of abductor forces on femoral stem stresses in cemented prosthetic hip replacement.

Orthopedics·2014
Same author

Early, design-related failure in total knee arthroplasty a case report.

Orthopedics·2014
Same author

Pyrolite carbon implants in the metacarpophalangeal joint of baboons.

Orthopedics·2014

Soluble APO-1 (sAPO-1) levels did not differ between multiple sclerosis patients and controls. This suggests sAPO-1 resistance is unlikely to cause abnormal lymphocyte apoptosis in multiple sclerosis.

Area of Science:

  • Immunology
  • Neuroscience
  • Cell Biology

Background:

  • Soluble APO-1 (sAPO-1) is implicated in preventing lymphocyte apoptosis via APO-1/Fas receptor activation.
  • Understanding sAPO-1's role is crucial for investigating autoimmune diseases like multiple sclerosis (MS).

Purpose of the Study:

  • To quantify serum sAPO-1 levels in MS patients and compare them with healthy controls.
  • To explore the potential link between abnormal lymphocyte apoptosis and MS pathogenesis.

Main Methods:

  • Serum samples were collected from patients diagnosed with MS, other neurological conditions, systemic lupus erythematosus, and healthy individuals.
  • Enzyme-linked immunosorbent assay (ELISA) was employed to measure sAPO-1 concentrations.

Main Results:

Related Experiment Videos

  • No significant differences were observed in mean serum sAPO-1 levels between MS patients and control groups.
  • These findings indicate that sAPO-1 levels are comparable in individuals with and without MS.

Conclusions:

  • This preliminary research suggests that sAPO-1-mediated resistance to lymphocyte apoptosis is not a primary driver of autoreactive cell development in MS.
  • Further investigation is warranted to fully elucidate the role of apoptosis in MS pathogenesis.